primary-intravitreal ranibizumab for high risk retinopathy of prematurity原发性济氏菌危险性逆转录病变.pdfVIP

CLINICALSCIENCE

PrimaryIntravitrealRanibizumabforHigh-Risk

RetinopathyofPrematurity

CarolineR.Baumal,MD;RogerA.Goldberg,MD;JordanaG.Fein,MD

INTRODUCTION

BACKGROUNDANDOBJECTIVE:Toevaluateinitial

treatmentofhigh-riskretinopathyofprematurityAblationoftheavascularretinawitheitherlaser

(ROP)withlow-doseintravitrealranibizumab.orcryotherapyisthetraditionaltreatmentforthresh-

oldandhigh-riskpre-threshold(type1)retinopathy

PATIENTSANDMETHODS:Caseseriesofprematureofprematurity(ROP).Despitetimelytherapy,unfa-

infantswithhigh-riskpre-thresholdorthresholdvorablestructuraloutcomesmayoccur.1,2Theremay

posteriorROPreceivingprimarytherapywith0.2alsobeadverseeffectsrelatedtothetreatmentmo-

mgranibizumab.Pre-treatmentandpost-injectiondality.RetinalablationforposteriorROPirreversibly

examination,RetCam(ClarityMedicalSystems,obliteratestheperipheralvisualfield.Increasedaxial

Pleasanton,CA)images,fluoresceinangiography,length,myopia,andcataractmayberelatedtoperiph-

resolutionofROPandplusdisease,andstabilityoferalablation.3,4Opticalcoherencetomography(OCT)

examinationswereassessed.ismorelikelytorevealfoveaabnormalitiesinchil-

drenwhoreceivedtreatmentforthresholdROPthan

RESULTS:Eighteyesoffourinfantsreceivedprimary